Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

PHASE4CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Back PainLow Back PainNeuropathic Pain
Interventions
DRUG

Tapentadol Prolonged Release

All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.

DRUG

Oxycodone/Naloxone Prolonged Release

All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.

Trial Locations (50)

1100

AT002, Vienna

3541

AT001, Senftenberg

10435

DE007, Berlin

10787

DE021, Berlin

12627

DE009, Berlin

13125

DE030, Berlin

15006

ES006, A Coruña

15526

DE005, Bad Saarow

15705

ES005, Santiago de Compostela

16132

IT001, Genova

18500

ES008, Guadix

19055

DE025, Schwerin

20253

DE031, Hamburg

21046

IT005, Varese

24105

DE001, Kiel

24106

DE027, Kiel

24119

DE014, Kiel

26655

DE024, Westerstede

27100

IT004, Pavia

28046

ES002, Madrid

28050

ES010, Madrid

28850

ES009, Madrid

30159

DE013, Hanover

33009

ES004, Oviedo

39104

DE015, Magdeburg

43126

IT002, Parma

44787

DE020, Bochum

45355

DE032, Essen

50924

DE029, Cologne

51069

DE008, Cologne

55116

DE006, Mainz

60313

DE017, Frankfurt

60596

DE003, Frankfurt

65185

DE026, Wiesbaden

65187

DE022, Wiesbaden

69469

DE016, Weinheim

95125

IT003, Catania

04564

DE023, Böhlen

03050

DE028, Cottbus

01067

DE012, Dresden

02826

DE011, Görlitz

04103

DE004, Leipzig

04107

DE034, Leipzig

04109

DE018, Leipzig

09648

DE002, Mittweida

07407

DE010, Rudolstadt

07646

DE019, Stadtroda

08006

ES007, Barcelona

08916

ES001, Barcelona

08540

ES003, Centelles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Grünenthal GmbH

INDUSTRY

NCT01838616 - Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component. | Biotech Hunter | Biotech Hunter